Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug

Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug

Aerie Pharmaceuticals' (NASDAQ: AERI) Rhopressa has secured Food and Drug Administration approval for use as an alternative to beta blockers in glaucoma patients that fail to respond adequately to prostaglandin analogues (PGA). A significant number of glaucoma patients fall into this addressable patient pool and that has management hoping Rhopressa's once-daily dosing advantage can turn it into a top seller. 

If glaucoma is left untreated, it can cause blindness, and that's a big problem. While many patients receive glaucoma treatment, it's estimated that up to half of the 3 million Americans with glaucoma don't know they have it. There are 60 million cases of glaucoma worldwide, and according to the World Health Organization, glaucoma is the second leading reason why people lose their sight.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com